ProQR: Fourth Quarter Financial Overview

ProQR Therapeutics Reports Fourth Quarter Financial Results

ProQR Therapeutics NV, headquartered in Leiden, Netherlands, announced a net loss of $9.1 million for the fourth quarter.

This translates to a quarterly loss of $0.09 per share.

The company’s performance fell short of analyst expectations, as a consensus of three analysts polled by Zacks Investment Research had anticipated a loss of $0.08 per share.

During the quarter, the Dutch pharmaceutical company generated $5.5 million in revenue.

For the full year, ProQR reported a total loss of $47.7 million, or $0.45 per share, with annual revenue reaching $18 million.

Financial data for this report was provided by Zacks Investment Research and compiled by Automated Insights.